Extended 10-Panel
Broad 10-substance screening covering CDT, cocaine, ketamine, amphetamines, 3-MMC, LSD, GHB, phenibut, heroin marker, and opiates.
Every result includes a professional assessment from a BIG-registered doctor. For treatment decisions, discuss your results with your GP.
An LSD urine test is a qualitative screening that detects the presence of lysergic acid diethylamide (LSD) or its metabolites in urine. LSD is a potent synthetic psychedelic substance that produces effects at very low doses.
This test detects the presence of LSD and its primary metabolite 2-oxo-3-hydroxy-LSD in urine. Due to the extremely low doses at which LSD is active, detection requires highly sensitive analytical methods. The test provides a qualitative result indicating whether LSD or its metabolites are present above the assay cut-off level.
LSD is not included in standard workplace drug screening panels, and specialised immunoassay or mass spectrometry methods are required for reliable detection.
LSD detection is relevant for clinical toxicology, forensic investigations, and extended drug screening programmes. The substance is active at microgram doses, making detection analytically challenging.
Targeted testing may be requested when LSD use is suspected in clinical or forensic settings where standard drug panels would not identify its presence.
Testing may be relevant when LSD use is suspected, as part of extended drug screening panels, or during forensic evaluations. Due to the short detection window, timely sample collection is important.
Consult a healthcare professional for guidance on appropriate testing methods and interpretation of results.
This marker is included in the following test panels.
Broad 10-substance screening covering CDT, cocaine, ketamine, amphetamines, 3-MMC, LSD, GHB, phenibut, heroin marker, and opiates.